Disease Domain | Count |
---|---|
Neoplasms | 6 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Synthetic peptide | 2 |
Herbal medicine | 2 |
CRISPR/Cas9 | 1 |
Target |
Mechanism LCN2 inhibitors [+2] |
Originator Org. |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD4 modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism αvβ3 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date17 Jun 2025 |
Sponsor / Collaborator ![]() [+10] |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date10 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LM49 ( CD4 ) | Diabetic Nephropathies More | Phase 1 |
Hydroxysafflor Yellow A ( LCN2 x STAT3 x ZBP1 ) | Neuroinflammation More | Preclinical |
RGD-Ce/CD ( αvβ3 ) | Neoplasms More | Preclinical |
Inulin-type fructan CP-A ( Akt x EGFR x ERK ) | Colorectal Cancer More | Preclinical |
DA5-CH ( GIPR x GLP-1R ) | Alzheimer Disease More | Preclinical |